GENOME EDITING TECHNOLOGIES IN THE TREATMENT OF DIABETES
Using various bioengineering methods to edit genes in order to treat diabetes
DOI:
https://doi.org/10.47611/jsrhs.v13i1.6410Keywords:
Bioengineering, Cell and Tissue engineering, Diabetes, genome editing technologies, CRISPR, ZFN, TALENsAbstract
This research paper will first introduce diabetes as a disease and briefly talk about all three types of diabetes as well. The symptoms, diagnosis, and consequences of having diabetes will also be discussed. Later, how the research question, “What are the various types of genome editing technologies that can be used to treat diabetes and what are their consequences?”, relates to diabetes and why it is important would be explained, along with a possible hypothesis that it could answer. In addition to that, how the research question tries to resolve the problem of diabetes would be underlined and a few solutions would be skimmed upon, which are the genome editing technologies: ZFN, TALENS, and CRISPR.
Downloads
References or Bibliography
(1)CDC. What is Diabetes? Centers for Disease Control and Prevention. https://www.cdc.gov/diabetes/basics/diabetes.html#:~:text=Diabetes%20is%20a%20chronic%20(long.
(2)Monogenic Diabetes (Neonatal Diabetes Mellitus & MODY) | NIDDK. National Institute of Diabetes and Digestive and Kidney Diseases. https://www.niddk.nih.gov/health-information/diabetes/overview/what-is-diabetes/monogenic-neonatal-mellitus-mody#:~:text=The%20most%20common%20forms%20of.
(3)Millette, K.; Georgia, S. Gene Editing and Human Pluripotent Stem Cells: Tools for Advancing Diabetes Disease Modeling and Beta-Cell Development. Current Diabetes Reports 2017, 17 (11). https://doi.org/10.1007/s11892-017-0947-3.
(4)Joung, J. K.; Sander, J. D. TALENs: A Widely Applicable Technology for Targeted Genome Editing. Nature Reviews Molecular Cell Biology 2012, 14 (1), 49–55. https://doi.org/10.1038/nrm3486.
(5)Wikipedia Contributors. Transcription activator-like effector nuclease. Wikipedia. https://en.wikipedia.org/wiki/Transcription_activator-like_effector_nuclease.
(6)Millette, K.; Georgia, S. Gene Editing and Human Pluripotent Stem Cells: Tools for Advancing Diabetes Disease Modeling and Beta-Cell Development. Current Diabetes Reports 2017, 17 (11). https://doi.org/10.1007/s11892-017-0947-3.
(7)Gerace, D.; Martiniello-Wilks, R.; Nassif, N. T.; Lal, S.; Steptoe, R.; Simpson, A. M. CRISPR-Targeted Genome Editing of Mesenchymal Stem Cell-Derived Therapies for Type 1 Diabetes: A Path to Clinical Success? Stem Cell Research & Therapy 2017, 8 (1). https://doi.org/10.1186/s13287-017-0511-8.
(8)Hu, M.; Cherkaoui, I.; Misra, S.; Rutter, G. A. Functional Genomics in Pancreatic β Cells: Recent Advances in Gene Deletion and Genome Editing Technologies for Diabetes Research. Frontiers in Endocrinology 2020, 11. https://doi.org/10.3389/fendo.2020.576632.
(9)Rasul, M. F.; Hussen, B. M.; Salihi, A.; Ismael, B. S.; Jalal, P. J.; Zanichelli, A.; Jamali, E.; Baniahmad, A.; Ghafouri-Fard, S.; Basiri, A.; Taheri, M. Strategies to Overcome the Main Challenges of the Use of CRISPR/Cas9 as a Replacement for Cancer Therapy. Molecular Cancer 2022, 21 (1). https://doi.org/10.1186/s12943-021-01487-4.
(10)PDB101: Molecule of the Month: Glucose Transporters. RCSB: PDB-101. https://pdb101.rcsb.org/motm/208.
Published
How to Cite
Issue
Section
Copyright (c) 2024 Dhrishit Patel
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Copyright holder(s) granted JSR a perpetual, non-exclusive license to distriute & display this article.
